About two dozen drug manufacturers have curbed their deliveries of 340B drugs to contract pharmacies, including Teva Pharmaceuticals, Bayer, Eli Lilly, Merck and Pfizer.
Gov. John Bel Edwards signed the law, called the Defending Affordable Prescription Drug Costs Act, June 12. It dictates that “a manufacturer or distributor shall not interfere with a pharmacy contracted with a 340B entity.”
The legislation also cracks down on pharmacy benefit managers by blocking the PBM industry from reimbursing 340B entities less than the price of the procured drug and from “placing any additional requirements, restrictions or unnecessary burdens upon the 340B entity that results in administrative costs or fees.” Doing so is discriminatory, according to the new law.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.